Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sierra Oncology Inc
(NQ:
SRRA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 30, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sierra Oncology Inc
< Previous
1
2
Next >
Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way
January 25, 2022
Sierra Oncology spent just $3 million up front to acquire momelotinib.
Via
Investor's Business Daily
Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development
January 25, 2022
Sierra Oncology Inc (NASDAQ: SRRA) has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential...
Via
Benzinga
Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal
January 25, 2022
Sierra Oncology Inc (NASDAQ: SRRA) unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic, anemic, and previously treated with an FDA-...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 25, 2022
Gainers Sierra Oncology (NASDAQ:SRRA) stock rose 45.6% to $22.58 during Tuesday's pre-market session. The market value of their outstanding shares is at $339.9 million...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
January 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:
Via
Benzinga
Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis
August 06, 2021
Sierra Oncology Inc (NASDAQ: SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN) for AZD5153, a potent, and selective BRD4...
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
July 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
COVID-19
58 Biggest Movers From Yesterday
July 13, 2021
Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday. State Auto Financial Corporation (NASDAQ: STFC) shares...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.